Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted inside cells to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex. This prevents the enzyme from resealing single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of replication, and ultimately death of rapidly dividing cancer cells.

The prescribed dose of Irinotecan Kabi is determined by the treating oncologist based on factors such as the patient’s body surface area, disease stage, liver function, and prior treatment history. The prescriber tailors the regimen to achieve optimal efficacy while managing safety.

Irinotecan is classified as contraindicated in pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception. Limited data exist for breastfeeding, and the drug is generally not recommended while nursing due to potential infant exposure.

To order Irinotecan Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines, oxaliplatin, or targeted agents. It is often combined with fluoropyrimidines for synergistic effect and is especially valuable after progression on first‑line regimens, whereas agents like oxaliplatin act on DNA cross‑linking.

Irinotecan Kabi should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. During transport, cold‑chain conditions are required to maintain product stability. Once prepared for infusion, it should be used promptly according to the manufacturer’s instructions.

Irinotecan Kabi is given by intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with monitoring for infusion‑related reactions and supportive care measures as needed.

The most serious risks include severe neutropenia (especially febrile neutropenia), life‑threatening delayed diarrhea that can lead to colitis or intestinal perforation, and rare but severe allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential.

Patients with known hypersensitivity to irinotecan or any of its excipients should avoid the drug. It is also contraindicated in individuals with severe hepatic impairment, uncontrolled infections, or those receiving concurrent strong CYP3A4 or UGT1A1 inhibitors that cannot be safely managed.